Assessments of the Value of New Interventions Should Include Health Equity Impact.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 5, p. 489, doi. 10.1007/s40273-022-01131-z
- By:
- Publication type:
- Article
Works matching IS 11707690 AND DT 2022 AND VI 40 AND IP 5
Results: 7
1
2
Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2022
- By:
- Publication type:
- Journal Article
3
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.
- Published in:
- 2022
- By:
- Publication type:
- journal article
4
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2022
- By:
- Publication type:
- journal article
5
Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 5, p. 479, doi. 10.1007/s40273-022-01133-x
- By:
- Publication type:
- Article
6
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
- Published in:
- 2022
- By:
- Publication type:
- journal article
7
Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.
- Published in:
- 2022
- By:
- Publication type:
- journal article